Replies to post #378845 on Amarin Corp Plc (AMRN)

[ilovetech]

"Trap" best describes the mistake people often make when they assign their own values on a demographic, then draw on those assumptions to formulate their investment thesis. It's very common to see elderly people develop a disdain for swallowing pills. Adding just one pill to their existing regimen garners irrational pushback, and it's not something you can reason with. That's just one demographic. 50% of my brother's practice are diabetic. Perhaps education levels play a great part, but nonetheless, compliance is an issue. He was telling me about a patient's cholesterol profile, and I suggested Vascepa. He laughed, "I'm lucky if I can get him to stake a Statin." People have no idea how stupid people are with their own health choices. So yeah, the choice of taking one pill instead of "TWO" makes a huge impact on compliance. No question. Full stop period.

ILT

[Whalatane]

Thx for the psychological analysis re “ trap I’m in “
I’m shocked , absolutely shocked that everyone is not like me … and getting Vascepa for $2 a month .

Who to blame ? … well AMRN marketing seems an easy target .

What would drive Kaiser to only charge an ASCVD high risk patient such as myself …only $2 a month for V

Guess they figured out it was cheaper then having patients like myself in their ER .

A combo is a waste of time and money …. And since you are Mr DD …. Name one other combo drug in the CV area that’s a profit maker .

Salute to all U veterans out there .
Today we remember and recognize your service for us all

Kiwi